基于环糊精的抗肿瘤药物主客体递送系统研究进展  

Advancement of Cyclodextrin-Based Host-Guest Drug Delivery System for Antitumor Therapy

作　　者：刘小英[1,2,3] 陈方敏 张惠娟 于海军 LIU Xiao-Ying;CHEN Fang-Min;ZHANG Hui-Juan;YU Hai-Jun(College of Pharmacy,Jiangxi University of Traditional Chinese Medicine,Nanchang 330004,China;Center of Pharmaceutics,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;Yangtze Delta Drug Advanced Research Institute,Nantong 226133,China)

机构地区：[1]江西中医药大学,南昌330004 [2]中国科学院上海药物研究所,上海201203 [3]长三角药物高等研究院,南通226133

出　　处：《应用化学》2023年第7期964-975,共12页Chinese Journal of Applied Chemistry

基　　金：国家自然科学基金(No.U22A20328)资助。

摘　　要：恶性肿瘤是威胁人类健康的重大疾病。开发安全高效的抗肿瘤药物及其递送系统是改善抗肿瘤药物疗效的重要保证。近年来,基于环糊精的抗肿瘤药物主客体递送系统受到了广泛关注。环糊精是通过淀粉酶解获得的环状低聚糖,具有外部亲水内部疏水的特殊结构,在基因治疗、免疫细胞治疗、免疫靶向治疗和化疗中均得到了广泛的应用。本综述主要总结了环糊精作为抗癌药物递送载体近10年的相关进展,同时对主客体递送系统在癌症治疗方面的机遇和挑战进行了展望和讨论。Malignant tumors are major diseases that threaten human health.The development of safe and efficient antitumor drugs and their delivery systems is an important guarantee for improving the efficacy of antitumor drugs.In recent years,cyclodextrin-based antitumor drug host-guest delivery systems have received much attention.Cyclodextrins are cyclic oligosaccharides obtained by amylolytic enzymes with an external hydrophilic internal hydrophobic structure,and have been widely used in gene therapy,immune cell therapy,immune-targeted therapy,and chemotherapy.This review summarizes the advances related to cyclodextrins as antitumor drug delivery carriers,and also provides a perspective and discussion on the opportunities and challenges of host-guest delivery systems in oncology therapy.

关 键 词：恶性肿瘤 主客体递药系统 环糊精包合物 环糊精偶联物 环糊精聚合物 

分 类 号：O641.3[理学—物理化学]